Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
VLA enters the week in a difficult spot: a pipeline setback has driven the stock down 13% over the past month, and the borrow market shows no sign of short sellers backing away.
Availability in the lending pool remains extremely tight. Only about 8.7% of already-borrowed shares are still available to lend, meaning there is roughly one share left for every eleven already out on loan. That number briefly tightened to below 5% earlier in the week before easing fractionally. The 52-week low was 1.5%, hit during a more acute squeeze in mid-September, so the current level is not a new extreme, but it is still well into stressed territory. Cost to borrow is running at 18.4%, down from a peak above 30% in mid-September but more than triple its level from early September when availability was far looser. The message from the lending market is consistent: borrow demand is high, supply is constrained, and shorts are holding their ground.
The short score reinforces that picture, though with some softening at the margin. The ORTEX short score has drifted lower from around 70.6 at the end of September to 68.1 now, a move in the right direction for the company but still a reading that places VLA in the bottom 13th percentile of its sector on short positioning. Availability ranks in the 2nd percentile of the universe, essentially as tight as it gets.
The pipeline backdrop explains much of the pressure. A recent note flagged that Valneva withdrew its Lyme disease vaccine candidate, citing commercial uncertainties in the US market. That removes what had been a key growth driver for a company already carrying a negative return on assets. The EV/EBITDA multiple has compressed by about 1.5 turns over the past 30 days to 8.2x, consistent with a market repricing the pipeline. The price-to-book multiple has pulled back to 4.4x from roughly 5.3x a month ago. EPS momentum scores rank in the bottom 1st and 2nd percentiles over 30 and 90 days respectively, though the EPS surprise score sits at the 89th percentile, meaning the company has historically beaten estimates when it has reported. Analyst data is stale (last updated in mid-August) and carries no recent changes, so the Street's formal view adds little to this week's read.
Among institutional holders, the ownership register carries a few points of interest. Goldman Sachs appears as the third-largest reported holder at just over 4% of shares, a position that was entirely new as of its last June filing. Frazier Life Sciences added nearly 6.9 million shares in Q2, bringing its stake to 4.4%. Pfizer Venture Investments holds about 5% and has been static. Those are meaningful votes of confidence from healthcare-specialist capital, though none of the filings are recent enough to reflect the Lyme vaccine withdrawal.
Earnings history on VLA is thin but striking: the August 2026 print produced a one-day move of nearly 22% to the upside and held most of that gain over the following five days. The next scheduled event is November 12. With the stock down 13% over the past month to EUR 2.57, and borrow conditions this tight, any material news before that date, positive or negative, is likely to move against a backdrop where covering shorts is not straightforward.
The key variable to watch between now and the November print is whether the pipeline withdrawal prompts any further revision to revenue expectations or triggers institutional holders to reduce positions, given how little room there is in the lending pool for new short positioning.
See the live data behind this article on ORTEX.
Open VLA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
